Abstract
Introduction
The ends of linear chromosomes are protected from genomic instability by the DNA-protein complexes known as telomeres [1] . The DNA component of human telomeres comprised a repetitive TTAGGG sequence (and complimentary sequence on the opposite strand), up to 20 kb in length, and a 3Ј G-rich single-stranded overhang [2, 3] . The G-rich overhang invades the double-stranded telomeric repeats to form a t-loop, which protects the telomere from end-to-end fusions and unregulated nuclease digestion of the 3Ј overhang [4, 5] . The [6, 7] .
Telomerase, the specialized enzyme capable of reverse transcribing DNA, is required for complete replication of telomeres [8] . In human beings, the core enzyme comprises the protein hTERT, which contains a reverse transcriptase domain capable of catalysing the addition of a six nucleotide repeat onto the ends of telomeres [9] , and an RNA component, termed hTR or hTERC (TElomerase RNA Component), which contains a template region that is complementary to the human telomere sequence [10] . Telomerase [11, 12] . Both hTR and hTERT are significantly up-regulated in malignant cells compared to normal cell counterparts [13] . Other telomere/telomerase associated proteins [such as dyskerin, NucleOlar Protein-10 (NOP10), Non-Histone Protein-2 (NHP2) and Glycine Arginine Rich-1 (GAR1)] are required for assembly of a functional telomerase holoenzyme complex [14] . How telomerase is regulated in expression and activity beyond transcription control which is covered by several other reviews, and the consequences of its dysfunction, is the focus of the following sections. 
Epigenetic regulation of telomerase: recent findings beyond transcriptional control

Methylation
Regulation of hTERT transcription generally takes place at the promoter region which has been found to contain an abundance of CpG sites, common targets for methylation [17] . DNA [19] . It has been suggested that methylation status and its relation to hTERT expression is dependent on the cell type [20, 21] [20, 23] . Of course, telomerase regulation is complex, and hTERT promoter methylation is just one piece of the puzzle.
Telomerase activity has also been shown to be subjected to regulation by methylation of other regions such as the subtelomeric region [24] . This is the chromosomal region just proximal to the telomeric region which has been found to be highly methylated in mouse and human cells as reviewed previously [24] [25] [26] . A recent study has indicated that subtelomeric methylation may influence telomerase activity, and specifically whether a tumour maintains its telomeres with telomerase or through the alternative lengthening of telomeres (ALT) pathway [27] . The specific mechanisms of the ALT pathway are not well known, and it is only utilized by 10-15% of human tumours [28] . Ng [29] ) may be an activator of hTERT in a small variety of cancer cell lines tested [30] . SIRT1 (NAD-dependent deacetylase sirtuin-1, the human analogue to Sir2), however, has been suggested to be an inhibitor of telomerase activity [31] . Likewise, a recent study has shown that an isoform of P63, ⌬NP63␣, can induce TERT promoter activity in mice, and it was suggested that this may be due to the downregulation of SIRT1 [32] . Recent studies with resveratrol have also added to the speculation that SIRT1 may be involved in telomerase regulation. Resveratrol is one of the most commonly used molecules thought to activate sirtuins. It is a small molecule that has been shown to improve health and longevity in many of the same ways as targets of SIRT1 [33] . It has been suggested that resveratrol promotes health and longevity by acting through sirtuins, although this idea is still debated [34, 35] . It has also been shown that resveratrol activates telomerase in endothelial progenitor cells [35] and decreases telomerase activity in breast cancer cells [36] . Although it has not been shown that these modifications of telomerase activity are directly related to SIRT1 activity, it is an interesting area requiring more study. For more information on current studies looking into the pharmaceutical use of resveratrol as a telomerase inhibitor, refer to the section below. [37] . More than 1000 miRNAs are predicted to work in human biology in a complex regulation network, and several studies have shown that many miRNAs are deregulated in cancers [37] [38] [39] [40] [47] [48] [49] . Relatively little is known about the functions of TERRA, but they have been shown to be an integral part of telomeric heterochromatin [47, 48] , and possibly help maintain telomere architecture [49] , provide epigenetic protection of telomeres from DNA repair mechanisms and regulation of telomerase activity [50] . It is thought that TERRA block telomerase activity at the telomeres in at least two ways: by blocking the RNA component with its sequence complementarity [27, 48] and by recruiting heterochromatinizing activities to the telomeric regions [48] .
Non-coding RNAs
Several recent publications have supported the notion that TERRA molecules may function as telomerase inhibitors.
Researchers have found that TERRA are capable of duplexing with hTERC [48, 50] , and it has been shown that there are lower levels of TERRA molecules in tumours than in corresponding normal tissue [48, 51] . It has also been found that shorter telomeres have lower levels of TERRA molecules [48, 50] . Shorter telomeres may transcribe lower amounts of TERRA because of the decrease in template space. This would cause less impairment of telomerase activity and help explain why telomerase has been shown to be selectively active at critically short telomeres [48, 50] .
To [53] . Extensive [60] . Two mutations (See Table 1 [74, 75] . hTERT mutations show varying degrees of effect on telomerase activity, with both conserved and non-conserved amino acids being able to drastically reduce activity [59] . Dyskerin interacts with hTR prior to assembly of the holoenzyme and mutations in Dyskerin 1 (DKC1) are shown to significantly impair this interaction [76] . hTERT mutations do not show a strict linkage between mutation and disease, but rather may show an increased risk of disease in individuals with hTERT mutations. Oppositely, hTERC mutations show a strong linkage between mutation and disease; however, the correlation between genotype and phenotype is unclear [77] . [78] . Patients also display signs of premature aging including hair greying and hair loss, osteoporosis and poor dentition [14] . The vast majority of DC patients (80-90%) develop bone marrow abnormalities by the age of 30 [79] and bone marrow failure is the principal cause of early mortality [56] . Individuals with DC also have a predisposition to cancer with an 11-fold increase in all cancer types, an 1154-fold increase in frequency of tongue cancer, and a 196-fold increase in frequency of acute myeloid leukaemia (AML) compared to the general population [80] .
Consequences of genetic dysfunction of telomerase: medical genetics of telomerase
Dysfunction due to mutations in the human genes essential for telomerase function (TERT and TERC) exhausts the proliferative capacity of cells with a high turnover rate, such as the haematopoietic system and other tissues
) have been found in the template region of hTERC, which decrease telomerase activity to levels that are undetectable by the Telomeric Repeat Amplification Protocol (TRAP) assay [55]. The mutations in hTERT can affect its reverse transcriptase function, DNA-binding ability and protein-protein interaction strength
Dyskeratosis congenita
DC is a rare multisystem disorder defined by three clinical characteristics: oral leukoplakia, nail dystrophy and hyerpigmentation of the skin
Mutations in patients suffering from DC were initially discovered in the DKC1 gene (See Table 1 ) located on the X chromosome, which encodes dyskerin, a protein involved in stabilizing [54] P10L NA [55] Q31K NA [55] Q31E NA [55] F36V NA [56] I38T NA [55] K39E NA [54] P40R NA [56] E41K NA [54] K43E NA [55] T49M NA [55] R65T NA [54] T66A NA [54] T67I NA [55] H68Q NA [55] L72Y NA [56] Deletion L37del NA [56] TruB domain Missense S121G NA [56] R153W NA [56] Middle Region Missense S280R NA [56] PUA domain Missense K314R NA [55] L317F NA [57] L321V NA [54] R322Q NA [57] M350T NA [54] M350I NA [54] A353V NA [54] T357A NA [55] D359N NA [55] C-terminal region Missense P384L NA [56] P384S NA [56] A386T NA [55] L398P NA [55] G402E NA [56] G402R NA [54] T408I NA [55] P409L NA [55] S420Y NA [55] Deletion ⌬ from 493 NA [55] hTERT [69] 467T→C ND [70] Continued telomerase RNA and forming the enzyme complex [12] . The most common mutation found in DKC1 is a C→T nucleotide substitution, which results in the A353V missense mutation in the protein sequence. This mutation can be inherited or arise de novo [54] . Approximately half of DC patients have a mutation in the genes of the telomerase holoenzyme complex, hTERT, hTERC or DKC1 [81] . It is likely that the remaining 50% of patients have mutations in other telomere maintenance genes, such as the mutations found in TINF2, NHP2 and NOP10 [82] . The most common form of the disease shows X-linked inheritance (DKC1 mutations), with 90% of patients being male, although both autosomal dominant (hTERT, hTERC and TINF2 mutations) and autosomal recessive (NHP2 and NOP10 mutations) inheritance patterns are recognized [83, 84] .
Aplastic anaemia
AA is another bone marrow failure disease associated with telomerase mutations. The disease is rare with an incidence of one to five per million and defined by hypocellular bone marrow and low peripheral blood cell counts [63] . A few patients who initially presented with AA have been found to develop DC, suggesting that AA is a marker of more severe phenotypes [68] . The observation that AA patient leucocytes had significantly shorter telomeres than controls led researchers to screen patients for mutations in telomerase components [53] . In acquired AA, approximately 2.5% of patients have mutations in hTERC and 3.5% have mutations in hTERT (See Table 1 for list) [66] . The majority of hTERC mutations cluster in the pseudoknot region, which is essential for hTERT binding and telomerase enzymatic activity [53] . The identified hTERT mutations are spread throughout the gene and act by haploinsufficiency, not a dominant negative mechanism. hTERC mutations decrease telomerase activity through haploinsufficiency as well [66] .
Idiopathic pulmonary fibrosis
IPF is a much more common disease, with a prevalence of at least 90,000, than DC or AA, although the aetiology of the disease is unclear, as implied by idiopathic [85] . [86] . [92] . It is also probable that failure to stabilize telomeres prior to significant shortening could contribute to an increased genomic instability capable of promoting increased tumour development and progression [80] . Variations in hTERC and hTERT have been found to contribute to overall telomere length implying a potential role for these variations in cancer risk [93, 94] . Recent genome-wide association studies have been performed in order to define whether there is an association between telomerase SNPs and cancer risk.
There is conflicting data regarding the role of hTERT variations and increased risk of breast cancer [80] . Although some studies have found an association between breast cancer risk and telomerase SNP [90] , the most compelling data involve studies performed on a total of 1656 breast cancer samples and 2019 matched controls [95] . These compelling, high power studies did not find an association between increased breast cancer risk and the SNPs of the telomerase promoter [95, 96] [99] [100] [101] [102] [103] [104] . Unlike the studies involving breast cancer, an increased risk of prostate cancer was found to be associated with at least one hTERT variation that influences telomerase expression [105, 106] . Other studies have linked cancer risk and telomerase SNP for several cancers including the following: bladder cancer [106, 107] , ovarian cancer [108] and cervix cancer [106] . But 
Summary and perspectives
Telomerase regulation is complex and has important consequences not just for telomere length, but also for the development of disease.
Obtaining further insight into the role of telomerase gene regulation and therefore telomerase activity in disease development will serve to assist in the generation of enhanced therapies. Understanding how telomerase is regulated will also lead to improved targeting of telomerase as a therapy for genetic diseases and cancer.
